secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2022-08-25T23:59:59+00:00
Accession:  0000950170-22-017792
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Takeda terminates collaboration; Finch regains full rights to IBD candidates FIN-524 and FIN-525
--------------------------------------------------------------------------------

- Takeda terminated collaboration for convenience effective Nov 17, 2022; Finch regains worldwide rights to FIN-524 and FIN-525.
- Finch received over $44M total from Takeda ($10M upfront, $4M milestones, over $30M R&D reimbursement).
- Finch will receive royalty-free license to all data and intellectual property generated during the collaboration.
- Finch is conducting a portfolio review and assessing financial and strategic impact of the termination.
- No new revenue or guidance provided; future development path for IBD candidates uncertain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022017792/0000950170-22-017792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022017792/fnch-20220819.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-017792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer